
Sign up to save your podcasts
Or


Dr. Pedro Barata and Dr. Bridget Keenan discuss the innovative bioengineering allowing clinicians to target historically "immune-cold" tumors, the logistical evolution of bringing bispecific therapies safely into outpatient community clinics, and the complex future of predictive biomarkers and resistance mechanisms.
LINK TO FULL TRANSCRIPT
By American Society of Clinical Oncology (ASCO)4.5
3131 ratings
Dr. Pedro Barata and Dr. Bridget Keenan discuss the innovative bioengineering allowing clinicians to target historically "immune-cold" tumors, the logistical evolution of bringing bispecific therapies safely into outpatient community clinics, and the complex future of predictive biomarkers and resistance mechanisms.
LINK TO FULL TRANSCRIPT

319 Listeners

40 Listeners

17 Listeners

57 Listeners

3,360 Listeners

47 Listeners

337 Listeners

24 Listeners

228 Listeners

59 Listeners

469 Listeners

59 Listeners

195 Listeners

46 Listeners

4,242 Listeners